PL4032586T3 - Bakterioterapia na zapalenie jelita grubego wywołane przez clostridium difficile - Google Patents

Bakterioterapia na zapalenie jelita grubego wywołane przez clostridium difficile

Info

Publication number
PL4032586T3
PL4032586T3 PL22160187.5T PL22160187T PL4032586T3 PL 4032586 T3 PL4032586 T3 PL 4032586T3 PL 22160187 T PL22160187 T PL 22160187T PL 4032586 T3 PL4032586 T3 PL 4032586T3
Authority
PL
Poland
Prior art keywords
bacteriotherapy
clostridium difficile
difficile colitis
colitis
clostridium
Prior art date
Application number
PL22160187.5T
Other languages
English (en)
Inventor
Edwin J. Hlavka
Original Assignee
Ferring Microbiome Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Microbiome Inc. filed Critical Ferring Microbiome Inc.
Publication of PL4032586T3 publication Critical patent/PL4032586T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL22160187.5T 2010-02-01 2011-02-01 Bakterioterapia na zapalenie jelita grubego wywołane przez clostridium difficile PL4032586T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33728310P 2010-02-01 2010-02-01
US35118410P 2010-06-03 2010-06-03

Publications (1)

Publication Number Publication Date
PL4032586T3 true PL4032586T3 (pl) 2026-03-09

Family

ID=44319684

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22160187.5T PL4032586T3 (pl) 2010-02-01 2011-02-01 Bakterioterapia na zapalenie jelita grubego wywołane przez clostridium difficile
PL19176151.9T PL3564357T3 (pl) 2010-02-01 2011-02-01 Bakterioterapia zapalenia jelita grubego z clostridium difficile

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL19176151.9T PL3564357T3 (pl) 2010-02-01 2011-02-01 Bakterioterapia zapalenia jelita grubego z clostridium difficile

Country Status (15)

Country Link
US (9) US9629881B2 (pl)
EP (5) EP2531589B1 (pl)
AU (1) AU2011209940B2 (pl)
CA (1) CA2788558C (pl)
DK (2) DK4032586T3 (pl)
ES (4) ES2730828T3 (pl)
FI (1) FI4032586T3 (pl)
HR (2) HRP20251418T1 (pl)
HU (2) HUE073517T2 (pl)
LT (2) LT4032586T (pl)
PL (2) PL4032586T3 (pl)
PT (2) PT3564357T (pl)
RS (2) RS67388B1 (pl)
SI (1) SI3564357T1 (pl)
WO (1) WO2011094027A1 (pl)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2788558C (en) 2010-02-01 2015-11-24 Mikrobex, Inc. Bacteriotherapy for clostridium difficile colitis
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
CN103561752B (zh) * 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
EP2850202B1 (en) * 2012-05-18 2020-03-11 Genome Research Limited Methods and groups
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
MX367109B (es) 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
US9956282B2 (en) 2013-12-16 2018-05-01 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
CN114990099A (zh) 2015-05-11 2022-09-02 迈彼欧提克斯制药有限公司 用于使益生菌在使细菌于肠道中定植用途的固体颗粒上生长成益生菌生物膜的系统和方法
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
AU2016274757B2 (en) 2015-06-09 2019-02-07 Ferring Microbiome Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
RU2022101485A (ru) 2016-05-25 2022-04-27 Майбиотикс Фарма Лтд. Композиция и способы для микробиотной терапии
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11959125B2 (en) 2016-09-15 2024-04-16 Sun Genomics, Inc. Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample
KR102708641B1 (ko) 2016-09-27 2024-09-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
CA3076359A1 (en) 2017-10-13 2019-04-18 Rebiotix, Inc. Microbiome health index
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
WO2019213595A1 (en) 2018-05-04 2019-11-07 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
KR20210021023A (ko) 2018-06-14 2021-02-24 리바이오틱스, 인코퍼레이티드 미생물총 회복 요법 조성물 및 제조 방법
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
KR20210091119A (ko) * 2018-08-17 2021-07-21 베단타 바이오사이언시즈, 인크. 장내세균 불균형을 감소시키는 방법 및 마이크로바이옴을 회복시키는 방법
KR20210065969A (ko) 2018-09-27 2021-06-04 핀치 테라퓨틱스 홀딩스 엘엘씨 간질 및 관련 장애를 치료하기 위한 조성물 및 방법
JP2022513623A (ja) 2018-11-21 2022-02-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がんを処置するための方法および組成物
CN113905749A (zh) * 2019-01-16 2022-01-07 德克萨斯大学系统董事会 用于治疗免疫检查点抑制剂相关结肠炎的方法和组合物
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
CR20220257A (es) * 2019-11-11 2023-01-17 Sabine Hazan Equipo de muestra de heces para tratamiento de un individuo con una condición de salud con trasplante de microbiota fecal
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
AU2021284269A1 (en) 2020-06-01 2023-01-05 Ferring B.V. Vaginal microbiota compositions
WO2022051610A1 (en) 2020-09-04 2022-03-10 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US12011467B2 (en) 2021-05-18 2024-06-18 J. Craig Venter Institute, Inc. Bacterial formulation
EP4472701A1 (en) * 2022-02-01 2024-12-11 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Simplified method of preparing cells for patient administration
WO2025210272A1 (en) 2024-04-05 2025-10-09 Ferring B.V. Composition comprising lactobacillus species for vaginal therapies

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL257275A (pl) 1959-10-26
US3261761A (en) 1962-05-07 1966-07-19 Arthur W Anderson Method of freeze drying bacterial cultures
WO1984004037A1 (en) 1983-04-13 1984-10-25 Field Group Res Pty Ltd Enema bag
WO1989003219A1 (en) 1987-10-12 1989-04-20 Borody Thomas J Improved method for treatment of gastrointestinal disorders
DE3741180A1 (de) 1987-12-04 1989-07-06 Claus Dr Med Jansen Elektroakustischer wandler
DE3889547T2 (de) 1987-12-24 1994-11-17 Borody Thomas J Orthostatische waschlösungen.
CA1333564C (en) 1988-08-02 1994-12-20 Thomas Julius Borody Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
CA1337265C (en) 1988-08-04 1995-10-10 Thomas Julius Borody Oral antibody therapy for patients with lowered immune response and composition therefor
CA2051092C (en) 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5519014A (en) 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ATE256468T1 (de) 1990-10-22 2004-01-15 Gastro Services Pty Ltd Behandlung von nicht-entzündlichen darmerkrankungen
US5229374A (en) 1992-01-28 1993-07-20 Burton Albert F Method for treatment of lower gastrointestinal tract disorders
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
AUPM864894A0 (en) 1994-10-07 1994-11-03 Borody, Thomas Julius Treatment of bowel-dependent neurological disorders
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5656283A (en) 1995-06-08 1997-08-12 Ortho Pharmaceutical Corporation In-situ lyophilization of vaginal suppository in unit dose applicator and resultant product
AU7362096A (en) 1995-09-15 1997-04-01 Dale N. Gerding M.D. Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
US6103268A (en) 1995-11-03 2000-08-15 Borody; Thomas Julius Administering osmotic colonic evacuant containing a picosulfate
US5925354A (en) 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US5711446A (en) * 1996-01-16 1998-01-27 Sorenson Bioscience, Inc. Cryogenic freezing vial
US5902578A (en) 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AUPO665397A0 (en) 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
CA2307331C (en) 1997-10-20 2017-03-21 Sanofi Pasteur Biologics, Llc Passive immunization against clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6428783B1 (en) 1998-03-11 2002-08-06 Medtech Center, Inc. Bank of autochthonous strains of microorganisms and methods of its use for recovery of intestinal microbiocenosis of the men
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2000016618A1 (en) 1998-09-21 2000-03-30 21St Century Medicine, Inc. Improved cryoprotectant solutions
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US7430478B2 (en) * 2000-03-01 2008-09-30 Caridian Bct, Inc. Blood processing information system with blood loss equivalency tracking
FR2808689B1 (fr) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs
JP2001327280A (ja) 2000-05-23 2001-11-27 Lion Corp 菌用凍結保存液
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
WO2001097821A1 (en) 2000-06-19 2001-12-27 Mucoprotec Pty Ltd Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compositions therefor.
CA2416120A1 (en) 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ES2325059T3 (es) 2000-11-14 2009-08-25 Techlab, Inc. Metodo para diferenciar el sindrome del intestino irritable de la enfermedad inflamatoria intestinal (ibd) y para seguir personas con ibd usando la lactoferrina endogena total como marcador.
EP1339390A2 (en) 2000-12-06 2003-09-03 Pharmacia Corporation Laboratory scale milling process
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1502101B1 (en) 2001-09-06 2012-11-07 Straus Holdings Inc. Rapid and sensitive detection of cells and viruses
EP1300472A1 (en) 2001-10-02 2003-04-09 Stichting Top-Instituut Voedselwetenschappen A method for testing the effect of nutrients on gastrointestinal colonisation resistance of humans
GB0124580D0 (en) 2001-10-12 2001-12-05 Univ Reading New composition
EP1448987A4 (en) * 2001-12-10 2005-06-08 Ardais Corp SYSTEM AND METHODS FOR OBTAINING PATIENT SAMPLES IN CORRELATION WITH DATA
US20030161871A1 (en) 2001-12-19 2003-08-28 Geoffrey Hird Solubilized riboflavin
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
AU2003225973A1 (en) 2002-03-26 2003-11-11 Glaxo Group Limited A method for forming a laminate assembly and products formed thereby
EP1596872B1 (en) 2003-01-24 2011-06-22 Flora Technology Inc. Compositions and methods for restoring bacterial flora
GB0322791D0 (en) 2003-09-30 2003-10-29 Lifeforce Group Plc Blood co-processing for contingent autologous leukocyte transplantation
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20060008511A1 (en) 2004-07-08 2006-01-12 Jhy-Jhu Lin Probiotic products for pet applications
US7935334B2 (en) 2005-07-07 2011-05-03 Imagilin Technologies, LLC Probiotics as alternative medicines against infectious diseases
US7909806B2 (en) 2004-09-23 2011-03-22 Anthrogenesis Corporation Cord blood and placenta collection kit
EP1817432A2 (en) 2004-10-05 2007-08-15 Wyeth a Corporation of the State of Delaware Probe arrays for detecting multiple strains of different species
SG160326A1 (en) 2004-11-08 2010-04-29 Univ Yale Structure-based compound design involving riboswitches
US20080075901A1 (en) 2005-02-23 2008-03-27 Lee S Thomas Multilayer Films Including Cycloolefin Copolymer and Styrene-Butadiene Copolymer
US20060210448A1 (en) 2005-03-10 2006-09-21 Naishu Wang Fecal specimen collection, preserving and transport device and method
AU2006224760A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline Type II aripiprazole
US7607776B1 (en) 2005-10-24 2009-10-27 James Waller Lambuth Lewis Digital eye bank for virtual clinic trials
EP1974052A2 (en) 2005-12-21 2008-10-01 Yale University Methods and compositions related to the modulation of riboswitches
BRPI0620734A2 (pt) 2005-12-29 2012-09-18 Hill's Pet Nutrition, Inc método para melhorar o equilìbrio de bactérias benéficas e nocivas no trato gastrintestinal de um animal, uso de pelo menos um antioxidante, composição de ração, kit, e meio para comunicação de informação e/ou instruções
US20080008751A1 (en) 2006-07-10 2008-01-10 Michael Fox Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20080027353A1 (en) 2006-07-31 2008-01-31 Kliman Harvey J Method of making and using a library of biological information
EP2089076A2 (en) 2006-10-13 2009-08-19 Reliance Life Sciences Pvt., Ltd. Cultured melanocytes on biopolymers
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
WO2009042645A2 (en) 2007-09-24 2009-04-02 President And Fellows Of Harvard College The use of mice predisposed to develop ulcerative colitis and colon cancer to develop metabolic profiles associated with same
EP2211879B1 (en) 2007-10-26 2014-05-07 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
US20090138354A1 (en) 2007-11-25 2009-05-28 Herbert Zech Methods of Storing and Providing Samples of Cells and Tissue
US20090148540A1 (en) 2007-12-10 2009-06-11 Mi Hope Incorporated Antibacterial composition and method of production
US8338812B2 (en) 2008-01-16 2012-12-25 Micron Technology, Inc. Vertical spacer electrodes for variable-resistance material memories and vertical spacer variable-resistance material memory cells
US20110237549A1 (en) 2008-03-27 2011-09-29 Memorial Sloan Kettering Cancer Center Modulators of rna riboswitches
EP2310532B1 (en) * 2008-06-30 2014-05-07 The Washington University Methods of promoting weight loss and associated arrays
US20100008850A1 (en) 2008-07-14 2010-01-14 William John Martin Method of generating hydrogen in drinking water using an enerceutical product added to magnesium in a hydrogen permeable but solute impermeable container
EP2320742B1 (en) 2008-07-17 2016-12-21 Bioworks, Inc. Control of plant diseases using a combination of a trichoderma virens species and a rhizosphere competent trichoderma harzianum species
KR20110097754A (ko) 2008-08-11 2011-08-31 바이오렐릭스, 인크. 플라빈 유도체
US20100151019A1 (en) 2008-11-14 2010-06-17 Portola Pharmaceuticals, Inc. SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF
EP2376348A4 (en) 2008-12-10 2012-09-05 Merck Sharp & Dohme PACKAGING FOR OXYGEN-SENSITIVE PHARMACEUTICAL PRODUCTS
AU2010243273B2 (en) 2009-05-01 2016-06-16 Ferring B.V. Composition for the treatment of prostate cancer
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
US20120177650A1 (en) 2009-09-23 2012-07-12 Borody Thomas J Therapy for enteric infections
US8999360B2 (en) 2009-10-22 2015-04-07 Thomas Julius Borody Compositions and methods for treating extracellular parasitic infections
WO2011050397A1 (en) 2009-10-26 2011-05-05 Borody Thomas J Novel enteric combination therapy
CA2788558C (en) 2010-02-01 2015-11-24 Mikrobex, Inc. Bacteriotherapy for clostridium difficile colitis
US8853269B2 (en) 2010-02-04 2014-10-07 Copperhead Chemical Company Inc. Composition and method for treating infections and promoting intestinal health
WO2011107482A2 (en) 2010-03-01 2011-09-09 Institut National De La Recherche Agronomique Method of diagnostic of obesity
AU2011223049B2 (en) 2010-03-01 2015-06-18 Institut National De La Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
FI20105478A0 (fi) 2010-04-30 2010-04-30 Valtion Teknillinen Menetelmä tyypin 1 diabeteksen diagnosoimiseksi ja menetelmiä ja koostumuksia tyypin 1 diabeteksen puhkeamisen estämiseksi
US9707207B2 (en) 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
WO2012013861A2 (en) 2010-07-26 2012-02-02 Suomen Punainen Risti Veripalvelu Use of blood group status iii
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
CA2807242C (en) 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
WO2012033814A2 (en) 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
WO2012050513A1 (en) 2010-10-11 2012-04-19 Baeckhed Fredrik Method for identifying a risk of cardiovascular disease by analysing oral microbiota
CN103687604A (zh) 2011-03-01 2014-03-26 群体创新有限责任公司 用于治疗与致病生物膜相关之病症的材料和方法
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
WO2014152484A1 (en) 2013-03-14 2014-09-25 Regents Of The University Of Minnesota Freeze dried fecal microbiota for use in fecal microbial transplantation
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276060A1 (en) 2011-04-29 2012-11-01 Techlab, Inc. Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CA2846804A1 (en) 2011-08-26 2013-03-07 Microbiota Diagnostics, Llc Methods for diagnosing and treating cardiac defects
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
LT2750682T (lt) 2011-10-11 2016-10-10 Achim Biotherapeutics Ab Kompozicija, apimanti anaerobiškai auginamą žmogaus žarnyno mikroflorą
WO2013150331A1 (en) 2011-11-09 2013-10-10 Capsugel Belgium Nv Acid resistant banding solution for acid resistant two piece hard capsules
WO2013090825A1 (en) 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora
WO2013130773A2 (en) 2012-02-29 2013-09-06 Ethicon Endo-Surgery, Inc. Compositions of microbiota and methods related thereto
EP2636684A1 (en) 2012-03-09 2013-09-11 CSL Behring AG Prevention of infection
WO2013163582A1 (en) 2012-04-27 2013-10-31 Cedars-Sinai Medical Center Fungal mycobiome as probiotics, diagnostics and therapeutics
EP2850202B1 (en) 2012-05-18 2020-03-11 Genome Research Limited Methods and groups
WO2014006532A1 (en) 2012-07-02 2014-01-09 Dsm Ip Assets B.V. Capsules containing thymoquinone
US20140112985A1 (en) 2012-10-22 2014-04-24 Polonez Therapeutics Llc Method of prevention and treatment of clostridium difficile infection
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
CN104918624A (zh) 2012-11-26 2015-09-16 托马斯·朱利叶斯·波洛迪 恢复排泄物微生物群的组合物及其制造和使用方法
DK2925300T6 (da) 2012-11-29 2021-02-08 Progel Pty Ltd Mikropartikler omfattende et probiotikum, et reagens, der kan tværbindes, et denatureret protein, et polyolplastificeringsmiddel og trehalose
US9689602B2 (en) 2012-12-23 2017-06-27 Illuminate Consulting, Llc Method and apparatus for thermally protecting and/or transporting temperature sensitive products
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
US9192361B2 (en) 2013-02-26 2015-11-24 Christopher J Stevens Fecal microbiome transplant material preparation method and apparatus
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US20150037285A1 (en) 2013-07-03 2015-02-05 New York University Methods for efficient transfer of viable and bioactive microbiota
WO2015026235A2 (en) 2013-08-22 2015-02-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Production of probiotics by in vitro enrichment of beneficial microorganisms from human or animal microbiota
JP2015091647A (ja) 2013-09-30 2015-05-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 マーキング方法、レーザー転写フィルム、インク組成物、マークが施された転写対象可食物及びその製造方法
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
CA2986485A1 (en) 2015-05-22 2016-12-01 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
AU2016270750B2 (en) 2015-06-01 2022-06-16 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
AU2016274757B2 (en) 2015-06-09 2019-02-07 Ferring Microbiome Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10173160B2 (en) 2015-10-09 2019-01-08 Heinzen, Llc Effluent removal system and method of use
ITUB20169847A1 (it) 2016-01-05 2017-07-05 Wellmicro S R L Metodo per valutare lo stato di salute di un individuo
US20180000872A1 (en) 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
WO2020018668A1 (en) 2018-07-17 2020-01-23 Ferring B.V. Combination therapy comprising microbiota restoration therapy (mrt) compositions

Also Published As

Publication number Publication date
EP4032586A1 (en) 2022-07-27
DK3564357T3 (da) 2022-06-20
FI4032586T3 (fi) 2025-11-25
ES2623127T3 (es) 2017-07-10
US9629881B2 (en) 2017-04-25
HUE073517T2 (hu) 2026-01-28
LT3564357T (lt) 2022-07-11
US20170266241A1 (en) 2017-09-21
US20180243351A1 (en) 2018-08-30
EP4032586B1 (en) 2025-08-20
EP2531589B1 (en) 2017-04-05
PL3564357T3 (pl) 2022-08-08
WO2011094027A1 (en) 2011-08-04
US9463208B2 (en) 2016-10-11
US12102655B2 (en) 2024-10-01
US20160367607A1 (en) 2016-12-22
EP4663746A2 (en) 2025-12-17
US20130045274A1 (en) 2013-02-21
AU2011209940A1 (en) 2012-08-23
ES2730828T3 (es) 2019-11-12
EP3181684B1 (en) 2019-05-29
RS63299B1 (sr) 2022-07-29
EP3564357A1 (en) 2019-11-06
PT4032586T (pt) 2025-09-22
EP2531589A4 (en) 2014-02-19
EP3181684A1 (en) 2017-06-21
ES3053646T3 (en) 2026-01-23
US11446337B2 (en) 2022-09-20
DK4032586T3 (da) 2025-11-10
HRP20220751T1 (hr) 2022-09-02
US20240415899A1 (en) 2024-12-19
EP3564357B1 (en) 2022-04-06
CA2788558C (en) 2015-11-24
HUE059169T2 (hu) 2022-10-28
SI3564357T1 (sl) 2022-09-30
LT4032586T (lt) 2025-11-10
US20230076826A1 (en) 2023-03-09
CA2788558A1 (en) 2011-08-04
HRP20251418T1 (hr) 2026-01-02
AU2011209940B2 (en) 2015-08-20
RS67388B1 (sr) 2025-11-28
US20240252556A1 (en) 2024-08-01
US11986500B2 (en) 2024-05-21
AU2011209940A2 (en) 2012-08-30
EP2531589A1 (en) 2012-12-12
ES2916399T3 (es) 2022-06-30
US12303537B2 (en) 2025-05-20
PT3564357T (pt) 2022-06-14
US11944654B2 (en) 2024-04-02
US20140086877A1 (en) 2014-03-27
US20240122995A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
SI3564357T1 (sl) Bakterioterapija Clostridium Difficile colitisa
GB201016742D0 (en) Clostridium difficile antigens
DK4403579T3 (en) Formulering til anti-alfa4beta7-antistof
DK3327110T3 (en) Kassette til sterilitetstest
GB2498008B (en) State transition
GB2506331B (en) Seal member
DK2737264T3 (en) Startlogik til kølesystem
ZA201409097B (en) Solid state bioreactor adapted for automation
ZA201400678B (en) Alpha-amylase variants
SG10201505217WA (en) Chimeric clotting factors
SG11201400916XA (en) Clostridium difficile antibodies
IL232957A0 (en) A composition based on clostridium difficile toxin
SG11201406301TA (en) Clostridium difficile antigens
EP2925362A4 (en) ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
GB201105625D0 (en) Seal
HUE049421T2 (hu) Clostridium difficile dehidrogenáz és toxin mint biomarker
GB201107459D0 (en) Seal
ZA201403228B (en) Heterocyclypyri(mi)dinylpyrazole
GB201120213D0 (en) B0-U component seal
GB201109531D0 (en) vessel
ZA201402298B (en) Heterocyclylpyri (mi)dinylpyrazole as fungicidals
GB2500854B (en) Biosurface engineering
PL2495467T3 (pl) System uszczelniający
GB201010960D0 (en) Complex